Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Offers SelectMDx Prostate Cancer Test to Patients in Netherlands

NEW YORK (GenomeWeb) – MDxHealth announced today that it has partnered with the Andros Men's Health Clinic in the Netherlands to offer its SelectMDx liquid biopsy prostate cancer test to Andros' patients.

Under the terms of the deal, the clinic will offer the diagnostic to all patients considered at risk for prostate cancer, with over 500 patients to undergo testing in the first year of the partnership. SelectMDx will become available starting April 1.

Further terms of the deal were not disclosed.

SelectMDx is a non-invasive urine based test to identify men at risk for aggressive prostate cancer who may benefit from early detection and an initial prostate biopsy or MRI, MDxHealth said. A negative SelectMDx also helps identify men at very low risk for cancer.

"At our clinic we recently launched a program we call the Andros Center for Prostate Cancer to deliver precision diagnosis for prostate cancer," said Andros Co-founder and Medical Director Frans Debruyne in a statement. "Now we have further enhanced our diagnostic algorithm with the SelectMDx test. … We believe the test will aid in improved patient risk stratification, avoiding unnecessary biopsy procedures for low-risk men, as well as identifying men at risk for clinically significant cancer who may require treatment."